Purinergic P2 Receptor Antagonists
Compounds that bind to and block the stimulation of PURINERGIC P2 RECEPTORS.
|Drug||Drug Name||Drug Indication|
|DB00208||Ticlopidine||Used in patients, who have had a stroke or stroke precursors and who cannot take aspirin or aspirin has not worked, to try to prevent another thrombotic stroke.|
|DB00758||Clopidogrel||For the reduction of atherosclerotic events (myocardial infarction, stroke, and vascular death) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction, or established peripheral arterial disease.|
|DB05553||Regrelor||Investigated for use/treatment in cardiac surgery, coronary artery disease, thrombosis, and transfusion.|
|DB06441||Cangrelor||For use as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.|
|DB08816||Ticagrelor||Ticagrelor is indicated for the prevention of thrombotic events like stroke or heart attack in patients with acute coronary syndrome or myocardial infarction with ST elevation.|